D-0466-2023 Class III Terminated
FDA drug recall D-0466-2023 was initiated by AVEVA Drug Delivery Systems, Inc. on Feb 15, 2023 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint. The recall status is terminated (terminated Apr 30, 2024). Affected quantity: 5,208 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 22, 2023
- Initiation Date
- Feb 15, 2023
- Termination Date
- Apr 30, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 5,208 cartons
Product description
Buprenorphine Transdermal System, CIII 20 mcg/hour, 4 Transdermal Systems One package of 4 disposal units, Rx Only, Manufactured by: Aveva Drug Delivery Systems Inc. Miramar, FL. 33025, Manufactured for: Apotex Corp Weston, FL. 33326, NDC 60505-7079-05
Reason for recall
Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint.
Distribution pattern
Nationwide
Code information
Lot#: 51836 Exp: 07/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0466-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026